Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Kisan Ratilal Choksey Shares and Securities Private Limited
$58.00
Provider: Motilal Oswal Securities Ltd.
$81.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sun Pharmaceutical Industries Ltd Announces USFDA Approval For Generic Depo-Testosterone Injection


Tuesday, 4 Jun 2013 06:30am EDT 

Sun Pharmaceutical Industries Ltd announced that it has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Depo-Testosterone Injection, Testosterone Cypionate Injection USP, 100 mg/ml and 200mg/ml. This generic Testosterone Cypionate Injection USP, 100 mg/mL and 200mg/mL is therapeutically equivalent to Depo-Testosterone Injection of Pfizer Inc and is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. As per April-2013, IMS MAT, the product had annual revenues of approximately USD130 million in the US.